Study of Pegylated Human Recombinant Arginase for Liver Cancer
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether recombinant human arginase (PEG-BCT-100) is
safe and effective in the treatment of advanced hepatocellular carcinoma (HCC).
Phase:
Phase 1
Details
Lead Sponsor:
Bio-Cancer Treatment International Limited
Collaborators:
Chinese University of Hong Kong The University of Hong Kong